Tuesday, July 27, 2021 Daily Archives

PerkinElmer continues M&A path with $5.25bn BioLegend deal

by

PerkinElmer is set to add antibody and reagent supplier BioLegend in a deal that analysts say could transform its Discovery and Analytical Solutions (DAS) business into a high growth segment. The acquisition announced yesterday and expected to close by the end of the year will see life sciences giant PerkinElmer pay $5.25 billion – including $2.2 billion in stock consideration – for private antibody and reagent developer BioLegend. The proposed deal xpands PerkinElmer into the “fast growing, high margin, antibody…

July 27, 2021

Cytiva & Pall: Chromotography, cell culture and SUS to benefit from $1.5bn boost

by

The investment will expand manufacturing capacity for life sciences products at thirteen Danaher Corporation sites run by Cytiva and Pall to meet customer demand.  The $1.5 billion investment is in addition to Cytiva’s $500 million growth strategy that was announced in September 2020 and  announced in January, and will fund expanding existing facilities as well as constructing new facilities in the US and the UK over the course of two years. More than $600 million will be invested in chromatography…

July 27, 2021